# BIONNA Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bionna-medicine

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.bionna.cn/
- Latest round: Series B (Aug 13, 2025)
- Investors on record: 8

## About

Based in China, BIONNA Medicine is a pharmaceutical company specializing in the development and commercialization of innovative solutions for respiratory diseases, focusing on both active ingredients and comprehensive manufacturing services.Founded in 2016 in Beijing, China, BIONNA Medicine is dedicated to providing pharmaceutical solutions, particularly for respiratory ailments. The company has engaged in 4 deals to date and raised funding through a Series B++ round in August 2025. The founder's background information is not available at this time.BIONNA Medicine specializes in the development and commercialization of pharmaceutical solutions targeting respiratory diseases. Their offerings include active pharmaceutical ingredients (APIs), intermediates, contract research organization (CRO) services, and contract development and manufacturing organization (CDMO) services. By focusing on a Quality by Design (QBD) approach, they enhance the efficacy and safety of small molecule drugs, serving a diverse clientele in international markets across Asia, Europe, and North America.BIONNA Medicine generates revenue through its extensive suite of pharmaceutical development and manufacturing services, primarily via a B2B model. Clients engage the company for its expertise in drug development, with revenue sources stemming from contractual arrangements for specific projects, such as research agreements and manufacturing contracts. Although specific pricing plans and revenue figures are not disclosed, their innovative solutions in respiratory disease therapeutics position BIONNA as a key player in the pharmaceutical supply chain.BIONNA Medicine aims to expand its product offerings with new pharmaceutical solutions targeted for launch in upcoming years. The company is also planning to enter additional international markets, specifically targeting regions across Asia and Europe by 2026. The recent Series B++ funding, raised from Changshu Guofa Venture Capital in August 2025, will be utilized to support these growth initiatives, enhancing their development and manufacturing capabilities.

## Funding rounds

- Series B, Aug 13, 2025 — Changshu Guofa Venture Capital
- Series B, Jan 19, 2025 — Sealand Innovation
- Series B, Aug 7, 2023 — Jinkong Qiyuan Capital, Shandong New Growth Drivers Fund Management, Healthib Capital, Yantai Jiuyin Equity
- Series A, Mar 9, 2020 — BrightGene Bio-Medical Technology Co., Ltd., Suzhou Longmen Venture Capital

## Investors

- BrightGene Bio-Medical Technology Co., Ltd. — Series A
- Suzhou Longmen Venture Capital (https://capitalatlas.ai/funds/suzhou-longmen-venture-capital) — Series A
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series B
- Shandong New Growth Drivers Fund Management (https://capitalatlas.ai/funds/shandong-new-growth-drivers-fund-management) — Series B
- Healthib Capital — Series B
- Yantai Jiuyin Equity — Series B
- Sealand Innovation (https://capitalatlas.ai/funds/sealand-innovation) — Series B
- Changshu Guofa Venture Capital (https://capitalatlas.ai/funds/changshu-guofa-venture-capital) — Series B